Pfizer Pipeline. February 28, 2012
|
|
- Harvey Douglas
- 6 years ago
- Views:
Transcription
1 Pfizer Pipeline February 28, 2012
2 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of February 28, Visit Pfizer.com/pipeline, Pfizer s online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world. 2
3 Table of Contents Pfizer Pipeline Snapshot 4 Cardiovascular & Metabolic Diseases 5 Inflammation & Immunology 6 Neuroscience & Pain 7 Oncology 9 Vaccines 10 Other Areas of Focus 11 Projects Discontinued Since Last Update 12 3
4 Pfizer Pipeline Snapshot Discovery Projects 12 programs advanced or are new Pfizer Pipeline Snapshot as of February 28, In Reg Total 90 Pipeline represents progress of R&D programs as of 2/28/12 Included are 70 NMEs plus 20 additional indications Discovery Projects 8 Projects discontinued since last update 6 programs advanced or are new Recent Approvals - Vyndaqel (tafamidis meglumine) for treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy (EU) - Prevnar 13 Adult for prevention of pneumococcal pneumonia and dinvasive i disease in adults 50 years of age and older (U.S.) - Inlyta (axitinib) for advanced renal cell carcinoma (U.S.) Pfizer Pipeline Snapshot as of November 11, In Reg Total 95 Pipeline represents progress of R&D programs as of 11/10/11 Included are 72 NMEs plus 23 additional indications 12 Projects discontinued since last update Recent Approvals - Xalkori (crizotinib) for ALK-Positive Non- Small Cell Lung Cancer (U.S.) - Prevenar 13 Adult for prevention of invasive pneumococcal disease in adults 50 years of age and older (EU) 4
5 Pfizer Pipeline February 28, 2012 Therapeutic Area Cardiovascular and Metabolic Diseases Compound Name Viviant Eliquis (apixaban) Mechanism of Action ( 3 through regulatory approval) Selective Estrogen Receptor Modulator Factor Xa Inhibitor Osteoporosis Treatment and Prevention (U.S.) Stroke Prevention in Atrial Fibrillation (U.S./EU) apixaban Factor Xa Inhibitor Venous Thromboembolism Prevention (U.S.) 3 Eliquis (apixaban) Factor Xa Inhibitor Venous Thromboembolism Treatment 3 PF Diabetes Mellitus-Type 2 2 PF Diabetes Mellitus-Type 2 2 RN316 (PF ) Hypercholesterolemia, Post Acute Coronary Syndrome in Diabetics (Biologic) 2 PF Diabetes Mellitus-Type 2 2 CVX 096 (PF ) Diabetes Mellitus-Type 2 (Biologic) 1 OAP-189 (PF ) Diabetes Mellitus-Type 2, Obesity (Biologic) 1 PF Diabetic Nephropathy 1 PF Diabetes Mellitus-Type 2 (Biologic) 1 PF Diabetes Mellitus-Type 2 1 PF Diabetes Mellitus-Type 2 1 PF Osteoporosis Treatment and Prevention (Biologic) 1 Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com 5
6 Pfizer Pipeline February 28, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) tofacitinib (CP ) JAK Inhibitor Rheumatoid Arthritis (U.S./EU) tofacitinib (CP ) JAK Inhibitor Psoriasis (Oral) 3 PF Rheumatoid Arthritis 2 SBI-087 (PF ) Rheumatoid Arthritis, *Lupus (Biologic) 2 PF Ulcerative Colitis (Biologic) 2 Inflammation and Immunology anrukinzumab (IMA-638) Ulcerative Colitis (Biologic) 2 PF Crohn s Disease (Biologic) 2 PF tofacitinib (CP ) Crohn s Disease, Lupus, *Rheumatoid Arthritis (Biologic) Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn s Disease, Ulcerative Colitis 2 2 PF (EXC 001) Dermal Scarring 2 PD Lupus (Biologic) 1 PF Liver Fibrosis 1 Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com * Note: Additional indications in 1 6
7 Pfizer Pipeline February 28, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) Neuroscience & Pain tafamidis meglumine Transthyretin (TTR) Dissociation Inhibitor Transthyretin familial amyloid polyneuropathy (U.S.) Lyrica Alpha-2 Delta Ligand Central Neuropathic Pain due to Spinal Cord Injury (U.S.) Celebrex COX-2 Chronic Pain (U.S.) Remoxy (King) ALO-02 Oxycodonenaltrexone core (King) Mu-type opioid receptor (MOR-1) Agonist Mu-type opioid receptor (MOR-1) Agonist Moderate to Severe Pain (U.S.) Moderate to Severe Pain 3 bapineuzumab Beta AmyloidInhibitor Alzheimer s Disease (Biologic) 3 Lyrica Alpha-2 Delta Ligand Peripheral Neuropathic Pain 3 Lyrica Alpha-2 Delta Ligand CR (once a day dosing) 3 tanezumab Nerve Growth Factor Inhibitor OA Signs and Symptoms (Biologic) (On Clinical Hold) 3 PF Schizophrenia 2 Eladur (King) Chronic Pain 2 PF Stroke Recovery 2 tanezumab Cancer Pain (Biologic) 2 PF Tourette s Syndrome 2 Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com 7
8 Pfizer Pipeline February 28, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) PF Acute Pain, *Chronic Pain 2 PF (AAB-003) Alzheimer s Disease (Biologic) 1 Neuroscience & Pain (cont d) PF Schizophrenia, Sensorineural Hearing Loss 1 Vabicaserin (PF ) Schizophrenia 1 PF (SAM-760) Alzheimer s Disease 1 PF Migraine (Biologic) 1 PF Schizophrenia 1 PF Alzheimer s Disease 1 PF Severe Chronic Pain 1 Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com * Note: Additional indications in 1 8
9 Pfizer Pipeline February 28, 2012 (cont d) Therapeutic Area Oncology Compound Name crizotinib axitinib bosutinib dacomitinib (PF ) Xalkori (crizotinib) Mechanism of Action ( 3 through regulatory approval) c-met-alk Inhibitor VEGF Tyrosine Kinase Inhibitor Abl and src-family kinase inhibitor Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer (EU) Advanced Renal Cell Carcinoma after failure of prior systemic treatment (EU) Previously Treated Chronic Myelogenous Leukemia (U.S.), Chronic Myelogenous Leukemia (EU) pan-her Inhibitor Non-Small Cell Lung Cancer 3 c-met-alk Inhibitor ALK-Positive 1 st and 2 nd Line Non-Small Cell Lung Cancer, *Cancer 3 Inlyta (axitinib) VEGF Tyrosine Kinase Inhibitor Advanced Renal Cell Carcinoma in treatment-naïve patients 3 Sutent Multiple Tyrosine Kinase Inhibitor Renal Cell Carcinoma Adjuvant 3 Torisel FKBP-Rapamycin Associated Protein Renal Cell Carcinoma 3 inotuzumab ozogamicin Aggressive Non-Hodgkin s Lymphoma (Biologic) 3 inotuzumab ozogamicin Indolent Non-Hodgkin s Lymphoma, *Acute Lymphocytic Leukemia (Biologic) 2 axitinib Liver Cancer, Thyroid Cancer 2 dacomitinib (PF ) Cancer 2 PD Cancer 2 CVX 060 (PF ) Renal Cell Carcinoma, *Cancer(Biologic) 2 Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com * Note: Additional indications in 1 9
10 Pfizer Pipeline February 28, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) PF Endometrial Cancer, *Cancer 2 PF Endometrial Cancer, *Cancer 2 PF Cancer 1 Oncology (cont d) PF Cancer (Biologic) 1 PD Cancer (in combination with PF ) 1 PF Cancer (Biologic) 1 PF Cancer (Biologic) 1 Vaccines PF Cancer 1 ACC-001 (PF ) Alzheimer s Disease 2 MnB rlp2086 (PF ) 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF ) Adolescent Meningitis, *Infant Meningitis 2 Staph Aureus 2 Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com * Note: Additional indications in 1 10
11 Pfizer Pipeline February 28, 2012 (cont d) Therapeutic Area Other Areas of Focus Compound Name Mechanism of Action ( 3 through regulatory approval) Taliglucerase alfa Enzyme Replacement Therapy Gaucher Disease (Biologic) Xiapex (EU) Clostridial Collagenase for Injection Peyronie s Disease (Biologic) (EU) 3 Eraxis/Vfend Beta-D Glucan Synthase Inhibitor, Cyp P450 Mediated Alpha-lanosterol Demethylation Aspergillosis 3 Zithromax/chloroquine 5-OS Ribosome Inhibitor Malaria 3 bazedoxifeneconjugated estrogens Tissue Selective Estrogen Complex Menopausal Vasomotor Symptoms 3 bosutinib Autosomal Dominant Polycystic Kidney Disease 2 PF (filibuvir) Hepatitis C Virus 2 tofacitinib (CP ) Transplant Rejection, Dry Eye 2 PH Chronic Obstructive Pulmonary Disease 2 PF (GMI-1070) Vaso-occlusive crisis associated with Sickle Cell Disease 2 PNU Tuberculosis 2 PF Chronic Renal Failure 2 RN6G (PF ) Age-Related Macular Degeneration (Biologic) 1 PF Chronic Obstructive Pulmonary Disease 1 PF Hemophilia (Biologic) 1 Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com 11
12 Projects Discontinued from Development since November 10, 2011 Compound Name Mechanism of Action ( 3 through regulatory approval) Pristiq Serotonin Norepinephrine Reuptake Inhibitor Vasomotor Symptoms of Menopause (U.S.) latrepirdine (Dimebon) MpTp Modulator Alzheimer s Disease 3 Lyrica Alpha-2 Delta Ligand Epilepsy Monotherapy 3 SD-6010 Osteoarthritis 2 PF Liver Fibrosis 2 PF Anti-Inflammatory 1 PF Cancer 1 PF Vasomotor Symptoms (Biologic) 1 12
Pfizer Pipeline. May 10, 2012
Pfizer Pipeline May 10, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
More informationPfizer Pipeline. August 9, 2012
Pfizer Pipeline August 9, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
More informationPfizer Pipeline. November 8, 2012
Pfizer Pipeline November 8, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
More informationPfizer Pipeline. As of May 12, 2011
Pfizer Pipeline As of May 12, 2011 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)
More informationDelivering Scientific Advances That Impact Patients Lives
Delivering Scientific Advances That Impact Patients Lives Geno Germano President / General Manager Specialty Care & Oncology Business Units J.P. Morgan Healthcare Conference January 11, 2011 Forward-Looking
More informationPfizer Worldwide Research & Development Presentation by Mikael Dolsten, M.D., PhD. Morgan Stanley Global Healthcare Conference September 13, 2010
Pfizer Worldwide Research & Development Presentation by Mikael Dolsten, M.D., PhD. Morgan Stanley Global Healthcare Conference September 13, 2010 Forward-Looking Statements Our discussions during this
More informationPfizer Pipeline. As of January 30, 2018
Pfizer Pipeline As of January 30, 2018 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)
More informationPfizer Pipeline. As of May 1, 2018
Pfizer Pipeline As of May 1, 2018 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)
More informationHEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
More informationPfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
More informationCHRONIC TREATMENT GUIDELINES
CHRONIC TREATMENT GUIDELINES REGISTRATION OF CHRONIC CONDITIONS You can only access benefits for chronic medication, as listed below, if your prescribing/treating doctor or pharmacist registers your chronic
More informationPfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
More informationPharmacotherapy Handbook
Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University
More informationCardiovascular Health Controlling Both HDL And LDL is Important
Cardiovascular Health Controlling Both HDL And LDL is Important Reducing the Risk of Coronary Heart Disease 3 Relative Risk In 4 Years 2 1 0 Increased Risk 25 55 85 HDL Cholesterol (mg/dl) 100 160 220
More informationHow much do you know about illnesses or health problems for your parents, grandparents, brothers, sisters, and/or children? 1 A lot Some None at all
Family Health History Please answer each question as honestly as possible. There are no right or wrong answers to nay of the questions. It is important that you answer as many questions as you can. We
More informationR&D Pipeline (May 2010)
R&D Pipeline (May 2010) 1 Global development (1) Filed Stage in the Most Advanced Territory YM617 tamsulosin Alpha-1 receptor antagonist Lower urinary tract syndrome in male patients (June 2007) New indication
More informationMagellan Rx. A smarter approach to pharmacy benefits management
Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We
More informationSummary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
More informationMajor Health Awareness Days in 2016
Major Health Awareness Days in 2016 Whole year International Year of Pulses January All summer Big Red BBQ (Kidney Foundation) National Cervical Health Awareness Month February Ovarian Cancer Awareness
More informationPhoenix Remembrance Life
Phoenix Remembrance Life Field Underwriting Guide For agent use only. Not for distribution to the public as sales literature. Phoenix Remembrance Life is whole life insurance underwritten on a simplified
More informationR&D Pipeline (November 2005)
R&D Pipeline (November 2005) 1Japan (1)Filed Code No YM905 YM177 YM152 FK463 Generic Name (Filing Date ) solifenacin (Aug 2004) celecoxib (Dec 2002) finasteride (Dec1994) micafungin (July 2004) (Oct 2005)
More informationPast Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1
Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma
More information(212) Investors Contact: Ryan Crowe (212)
For immediate release: February 5, 2014 Media Contact: Sally Beatty (212) 733-6566 Investors Contact: Ryan Crowe (212) 733-8160 Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies
More informationR&D Pipeline (May 2006)
R&D Pipeline (May 2006) 1Japan (1)Approved Product Name (Code No) Vesicare (YM905) Funguard (FK463) (Approval Date ) solifenacin (April 2006) micafungin (April 2006) Urinary frequency, urinary incontinence
More informationPremium Specialty: Pediatrics
Premium Specialty: Pediatrics Credentialed Specialties include: Adolescent Medicine, Pediatric Adolescent, and Pediatrics This document is designed to be used in conjunction with the UnitedHealth Premium
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationWhat prescribers need to know
HUMIRA Citrate-free presentations in an Electronic Medical Record (EMR) What prescribers need to know 2 / This is your guide to identifying HUMIRA Citrate-free presentations in your Electronic Medical
More informationBarbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi
Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Joseph T. DiPiro, PharmD, FCCP Panoz Professor of Pharmacy, College
More informationR&D Pipeline (November 2006)
R&D Pipeline (November 2006) 1Japan (1)Filed Code No Generic Name (Filing Date ) Therapeutic Target Classification YM177 celecoxib (Dec 2002) Rheumatoid arthritis, osteoarthritis, low back pain, etc Cyclooxygenase-II
More informationHELPING YOU AND YOUR PATIENTS TALK OPENLY ABOUT MODERATELY TO SEVERELY ACTIVE RA
SIMPONI ARIA (golimumab) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with MTX, active psoriatic arthritis, and active ankylosing
More informationSimponi / Simponi ARIA (golimumab)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi
More informationCHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER
RAND WATER MEDICAL SCHEME RAND WATER MEDICAL SCHEME CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER LIST OF CHRONIC CONDITIONS Conditions covered under s chronic medication benefit are detailed below.
More informationXeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release)
Market DC Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release) Override(s) Prior Authorization Quantity Limit Medications Xeljanz (tofacitinib) Approval Duration 1 year Quantity Limit May be
More informationPfizer Announces Modification To Ongoing Tofacitinib FDA Post- Marketing Requirement Study In Patients With Rheumatoid Arthritis
February 19, 2019 Media Contact: Neha Wadhwa M: +1 212-733-2835 E: Neha.Wadhwa@pfizer.com Investor Contact: Charles Triano O: +1 212-733-3901 E: Charles.E.Triano@pfizer.com Pfizer Announces Modification
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018 WALK INS ARE ACCEPTED BUT WE ADVISE STUDENTS TO PRE-REGISTER BEFORE THURSDAY
SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs January 201 DATE DAY TIME TOPICS January 04 January 11 January 1 January 25 9:00AM 9:00AM 9:00AM 9:00AM 1. Understanding Fibromyalagia 2. Diabetes
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018
January 201 DATE DAY TIME TOPICS TOTAL January 04 1. Understanding Fibromyalagia 2. Diabetes and Cardiovascular Disease 3. Prostate Cancer 4. Hepatitis C 5. Understanding Hepatitis B January 11 1. Dysphagia
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2019
January 2019 DATE DAY TIME TOPICS TOTAL January 03 1. Alcoholism 2. Nutrition for the Elderly 3. Uterine Fibroids 4. HIPAA 5.Arthritis 6. Childhood Obesity January 10 1. Understanding Epilepsy: Latest
More informationActemra (tocilizumab) CG-DRUG-81
Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject
More informationRayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
More informationEnhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine
SMi Immuno-Oncology, London Loui Madakamutil, Ph. D Vice President, Head for Discovery Enhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine Sept 26-27 2018 Nektar Therapeutics San
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More information2016 Health and Wellness Observances
2016 Health and Wellness Observances January 2016 Notes HealthCom Cervical Health Awareness Month National Birth Defects Prevention Month Cervical Cancer Screening Month National Blood Donor Month National
More informationProfessional International Study Management
Professional International Study Management Services Phase I Study Consulting Phase II-IV IV Study Conduct for Drugs and Devices Protocol Design and Development Study Feasibilities Site Identification,
More informationPfizer Global Medical Grants Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals
In order to submit a request for general meeting support for an Annual Meeting, the answers to the following questions must be Yes : Does the activity align with Pfizer s Primary Areas of Interest? (listed
More informationList of Qualifying Conditions
List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)
More informationEvolve180 / Ideal Northwest Health Profile
Evolve180 / Ideal Northwest Health Profile ABOUT YOU First Name: Last Name: Address: City: State: Zip: Phone: Email: Date of Birth: Age: Height: Occupation: How did you find out about our program? Marital
More informationIntron A. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.07 Subject: Intron A Page: 1 of 6 Last Review Date: June 22, 2018 Intron A Description Intron A (interferon
More information*Compounds with "In-house" in this column include ones discovered by collaborative research.
AGS67E Lymphoid malignancies P-I Injection In-house (ADC technology in-licensed from Seattle Genetics) AGS62P1 Acute myeloid leukemia P-I Injection In-house (ADC technology, EuCODE license from Ambrx)
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 17, 2017 Xeljanz Description Xeljanz, Xeljanz
More informationJefferies Healthcare Conference. June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
More informationAsthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus
A Fib & Flutter I48.0 Paroxysmal atrial fibrillation I48.1 Persistent atrial fibrillation I48.2 Chronic atrial fibrillation I48.3 Typical atrial flutter Asthma J45.20 Mild, uncomplicated J45.21 Mild, with
More informationCHRONIC MEDICATION PROGRAMME INCLUDES PRESCRIBED MINIMUM BENEFIT CHRONIC DISEASE LIST (CDL)
CHRONIC MEDICATION PROGRAMME INCLUDES PRESCRIBED MINIMUM BENEFIT CHRONIC DISEASE LIST (CDL) A. GENERAL INFORMATION LIST OF CHRONIC CONDITIONS Conditions covered under KeyHealth s chronic medication benefit
More information2015 PQRS Registry. Source Measure Title Measure Description CITIUS1
1 CQ-IQ covers 65 CMS defined measures that Eligible Providers (EPs) have to report on to assess quality of care provided to the patients. Version Supported: PQRS Registry 2015 65 measures Reporting Period:
More informationWITBANK COALFIELDS MEDICAL AID SCHEME (WCMAS) CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER
WITBANK COALFIELDS MEDICAL AID SCHEME (WCMAS) CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER The Prescribed Minimum Benefit Chronic Disease List In terms of the Medical Scheme Act Regulations that
More informationR&D Pipeline (As of April 2017)
R&D Pipeline (As of April 2017) Underlined items indicate changes from the previous announcement on January 31, 2017. Oncology (1/2) MDV3100 enzalutamide Androgen receptor inhibitor Metastatic castration-resistant
More informationOver. Signature of Patient/Parent/Guardian: Date: / / Date: / / Patient s Name: For ADULT Patients : Employer: Address: Occupation:
Date: / / Patient s Name: Address: Preferred Home: ( ) - Work: ( ) - Cell: ( ) - Text Message Reminders : Yes No Social Security #: Date of Birth: - - / / For ADULT Patients : Employer: Occupation: Spouse
More informationStep Therapy Approval Criteria
Effective Date: 10/01/2016 This document contains Step Therapy Approval Criteria for the following medications: 1. Colcrys (colchicine) 2. Cymbalta (duloxetine) 3. Dovonex (calcipotriene) 4. Enbrel (etanercept)
More information2018 MIPS Reporting Family Medicine
2018 MIPS Reporting Family Medicine Quality Reporting Requirements: Report on 6 quality measures or a specialty measure set Include at least ONE outcome or high-priority measure Report on patients of All-Payers
More informationMEDICAL HISTORY FORM FOR FOLLOW-UP
MEDICAL HISTORY FORM FOR FOLLOW-UP ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: Whenever numerical responses are required, enter the number so that the last digit appears in the rightmost
More informationReproducibility with zebrafish models of human health and disease
Reproducibility with zebrafish models of human health and disease Monte Westerfield, University of Oregon, Eugene, USA Sponsored by the Office of the Director National Institutes of Health, the National
More informationIn your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed.
Name: SS# In your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed. Patient Medical, Surgical and Family History Review
More informationAre Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable.
Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable. BACKGROUND Your Host: Eric Bricker, MD Co-Founder & Chief Medical Officer - Compass Professional Health Services
More informationEVIDENCE-BASED VITAMIN AND MINERAL USAGE SUMMARY TABLE (APRIL 2002)
Acne Acrodermatitis Enteropathica Adrenal Support Age Related Cognitive Decline Alcoholism/Alcohol Withdrawal Alzheimer's Disease Amenorrhoea Anaemia Angina Anorexia Nervosa Anxiety Asthma Atherosclerosis
More informationMeasuring Long-Term Conditions in Scotland - A summary report
Measuring Long-Term Conditions in Scotland - A summary report Introduction This summary report provides insight into: What are the most common long-term conditions in Scotland? What is the population prevalence
More informationPROFMED MEDICAL SCHEME CHRONIC MEDICINE BENEFIT GENERAL INFORMATION
PROFMED MEDICAL SCHEME CHRONIC MEDICINE BENEFIT GENERAL INFORMATION The Prescribed Minimum Benefit Chronic Disease List In terms of the Medical Schemes Act Regulations that came into effect on 1 January
More informationIntron A. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.07 Subject: Intron A Page: 1 of 6 Last Review Date: June 24, 2016 Intron A Description Intron A (interferon
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationOverview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists
Overview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists Measure Name Measure Domain Measure Focus Comment/Explanation CMS Value-based Purchasing Program (CMS VBP) AMI 30-day
More informationJanuary Intravenous Nurse Day ALL MONTH LONG SUN MON TUE WED THU FRI SAT. Blood Donor Month. Glaucoma Awareness Month
January 1 2 3 4 5 6 Blood Donor Month 7 8 9 10 11 12 13 Glaucoma Awareness Month Volunteer Blood Donor Month Cervical Health Awareness Month 14 15 16 17 18 19 20 Thyroid Awareness Month Birth Defects Prevention
More informationCHRONIC MEDICINE PROGRAMME: GENERAL INFORMATION LETTER
CHRONIC MEDICINE PROGRAMME: GENERAL INFORMATION LETTER The Prescribed Minimum Benefit Chronic Disease List In terms of the Medical Scheme Act Regulations that came into effect on 1 January 2004, Medical
More informationSECTION I: ACTIVE DIAGNOSES. Active Diagnoses in the Last 7 Days
SECTION I: ACTIVE DIAGNOSES Intent: The items in this section are intended to code diseases that have a relationship to the resident s current functional status, cognitive status, mood or behavior status,
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
More informationStreptococcus pneumoniae CDC
Streptococcus pneumoniae CDC Pneumococcal Disease Infection caused by the bacteria, Streptococcus pneumoniae» otitis media 20 million office visits (28-55% Strep)» pneumonia 175,000 cases annually» meningitis
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationDevelopment status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
More informationGenentech Research & Early Development
Genentech Research & Early Development Founders Research Centers 1 & 2 Founders Research Centers 1 & 2 Andrew Chan, M.D., Ph.D. Senior Vice President, Research Biology September 2017 gred focus areas Discovering
More informationIntron A. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Page: 1 of 6 Last Review Date: June 19, 2015 Intron A Description Intron A (interferon
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 6 PURPOSE To establish basic understanding of indications and contraindications for transplantation of various organs. POLICY The N.C. Department of Correction, Division of Prisons, Health Services
More informationLECOM Health Ophthalmology
Patient Name: Date of Birth: New Patient Questionnaire Your answers will be used by your healthcare provider get an accurate history of your medical conditions and ocular concerns. If you are uncomfortable
More informationESC 2018 Tafamidis Analyst Briefing. August 27, 2018
ESC 2018 Tafamidis Analyst Briefing August 27, 2018 1 Forward Looking Statements This presentation includes forward-looking statements about, among other things, a potential indication for Tafamidis for
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),
More informationproposed set to a required subset of 3 to 5 measures based on the availability of electronic
CMS-0033-P 143 proposed set to a required subset of 3 to 5 measures based on the availability of electronic measure specifications and comments received. We propose to require for 2011 and 2012 that EP's
More informationDATE OF BIRTH: MELANOMA INTAKE
MELANOMA INTAKE GENERAL INFORMATION How was your first diagnosed? (Check the diagnosis that describes your condition.) Melanoma Merkel Cell Carcinoma Squamous Cell Carcinoma Basal Cell Carcinoma Other
More informationMEDICAL HISTORY FORM FOR FOLLOW-UP
MEDICAL HISTORY FORM FOR FOLLOW-UP ID NUMBER: 0a) Form Date... / / 0b) Staff Code... Instructions: Whenever numerical responses are required, enter the number so that the last digit appears in the rightmost
More informationCUMULATIVE ILLNESS RATING SCALE (CIRS)
CUMULATIVE ILLNESS RATING SCALE (CIRS) The CIRS used in this protocol is designed to provide an assessment of recurrent or ongoing chronic comorbid conditions, classified by 14 organ systems. Using the
More informationDevelopment status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
More informationCelecoxib Powder, Diclofenac Powder, Flurbiprofen Powder, Ibuprofen Powder, Ketoprofen Powder, Meloxicam Powder, Tramadol Powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.26 Subject: Anti-Inflammatory Pain Powders Page: 1 of 5 Last Review Date: December 3, 2015 Anti-Inflammatory
More informationEgg Donor screening Questionnaire. How many years did you complete in high school?
Please tick ( ) and complete ALL questions. YOU YOUR PARTNER Full name Forename Surname Forename Surname Date of birth day / month / year day / month / year Address Height : Weight: Ethnicity Home Tel:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Rayos) Reference Number: CP.CPA.273 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationInfliximab/Infliximab-dyyb DRUG.00002
Infliximab/Infliximab-dyyb DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Inflectra (inflectra-dyyb) Approval Duration 1 year Comment Intravenous administration
More informationCiti Global Healthcare Conference
Citi Global Healthcare Conference Francis Cuss, MB BChir, FRCP Chief Scientific Officer February 24, 2014 1 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationDevelopment pipeline (as of February 1, 2017)
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2016 (IFRS) 13 Development pipeline (as of February 1, 2017) Oncology Additional indication name
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
More informationMEDICAL HISTORY. Previous Nephrologist. Medication taken Insulin Oral Both. Who manages your diabetes? Blindness Yes No Hearing Problems Yes No
MEDICAL HISTORY Please mark YES or NO and fill in appropriate blanks as needed Chronic Yes No If yes, year diagnosed Previous Nephrologist Transplant Yes No If yes, date Donor type Living Deceased Related
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 18, 2016 Xeljanz Description Xeljanz, Xeljanz
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationUnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty
UnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty 666700 Acne Family Medicine, Internal Medicine, Pediatrics 438300 Acute Bronchitis Allergy,
More informationJefferies 2017 Global Healthcare Conference. Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer
Jefferies 2017 Global Healthcare Conference Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer June 7, 2017 This presentation includes forward-looking statements regarding Nektar
More information